Dendreon Rises After Winning Approval for Cancer Drug (Update2)
April 29 (Bloomberg) — Dendreon Corp. won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators. Shares surged the most in a year in New York trading.
Read more on Bloomberg